Recombinant Human Osteoprotegerin (Human OPG) _ C230467

Description

Osteoprotegerin (OPG), also called OCIF (osteoclastogenesis inhibitory factor) is a secreted 55-60 kDa protein that regulates bone density. As a member of the tumor necrosis factor receptor (TNFR) superfamily of proteins, it is designated TNFRSF11B. Human OPG cDNA encodes 401 amino acids (aa) including a 21 aa signal peptide and a 380 aa mature soluble protein with four TNFR domains, two death domains and a heparin-binding region. The cysteine-rich TNFR domains are essential for ligand interaction, while a cysteine at the C-terminus mediates homodimerization. Mature human OPG shares 86%, 87%, 92%, 92% and 88% amino acid sequence identity with mouse, rat, equine, canine and bovine OPG, respectively. OPG is widely expressed and constitutively released as a homodimer by mesenchymal stem cells, fibroblasts and endothelial cells. Regulation of its expression by estrogen, parathyroid hormone and cytokines is complex and changes with age. OPG has been called a decoy receptor for the TNF superfamily ligands, TRANCE (tumor necrosis factor-related activation-induced cytokine), also called RANK L (receptor activator of NF kappa B ligand), and TRAIL (TNF-related apoptosis-inducing ligand), which also bind TNF family receptors RANK and TRAIL receptors 1-4, respectively. TRAIL decreases the release of OPG from cells that express it, while OPG inhibits TRAIL-induced apoptosis. Expression of RANK L on the cell surface, and thus its ability to stimulate osteoclastogenesis, is regulated by OPG by intracellular and extracellular mechanisms. Within osteoblasts, interaction of the basic domain of OPG with RANK L in the Golgi inhibits RANK L secretion.

 

Product Properties

 

Synonyms

TNFRSF11B, Osteoclastogenesis Inhibitory Factor, Tumor Necrosis Factor Receptor Superfamily Member
11B

Accession
O00300
GeneID
4982

Source

E.coli-derived Human OPG, Glu22-Lys194.
Molecular Weight
Approximately 19.7 kDa.
AA Sequence
ETFPPKYLHY DEETSHQLLC DKCPPGTYLK QHCTAKWKTV CAPCPDHYYT DSWHTSDECL YCSPVCKELQ YVKQECNRTH NRVCECKEGR YLEIEFCLKH RSCPPGFGVV QAGTPERNTV
CKRCPDGFFS NETSSKAPCR KHTNCSVFGL LLTQKGNATH DNICSGNSES TQK
Tag
None
Physical Appearance
Sterile Filtered White lyophilized (freeze-dried) powder.
Purity
> 95 % by SDS-PAGE and HPLC analyses.
Biological Activity
The ED50 as determined by neutralizing the stimulation of U937 cells is less than 10 ng/mL, corresponding to a specific activity of > 1.0 × 10 5 IU/mg in the presence of 10 ng/mL soluble rHuRANKL (sRANKL). Fully biologically active when compared to standard.
Endotoxin
< 1.0 EU per 1μg of the protein by the LAL method.
Formulation
Lyophilized from a 0.2 μm filtered concentrated solution in 20 mM PB,150 mM NaCl, pH 6.0.
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20℃. Further dilutions should be made in appropriate buffered solutions.

 

Storage

 

The products are shipped with ice pack and can be stored at -20℃ to -80℃ for 1 year.
Recommend to aliquot the protein into smaller quantities when first used and avoid repeated freeze-thaw cycles.

 

Caution

 

1. Avoid repeated freeze-thaw cycles.
2. For your safety and health, please wear lab coats and disposable gloves for operation.
3. For research use only!

Recombinant Human Osteoprotegerin (Human OPG) _ C230467

Product form

SKU: C230467E

$74.00

      • Tell a unique detail about this product

      Description

      Osteoprotegerin (OPG), also called OCIF (osteoclastogenesis inhibitory factor) is a secreted 55-60 kDa protein that regulates bone density. As a member of the tumor necrosis factor receptor (TNFR) superfamily of proteins, it is designated TNFRSF11B. Human OPG cDNA encodes 401 amino acids (aa) including a 21 aa signal peptide and a 380 aa mature soluble protein with four TNFR domains, two death domains and a heparin-binding region. The cysteine-rich TNFR domains are essential for ligand interaction, while a cysteine at the C-terminus mediates homodimerization. Mature human OPG shares 86%, 87%, 92%, 92% and 88% amino acid sequence identity with mouse, rat, equine, canine and bovine OPG, respectively. OPG is widely expressed and constitutively released as a homodimer by mesenchymal stem cells, fibroblasts and endothelial cells. Regulation of its expression by estrogen, parathyroid hormone and cytokines is complex and changes with age. OPG has been called a decoy receptor for the TNF superfamily ligands, TRANCE (tumor necrosis factor-related activation-induced cytokine), also called RANK L (receptor activator of NF kappa B ligand), and TRAIL (TNF-related apoptosis-inducing ligand), which also bind TNF family receptors RANK and TRAIL receptors 1-4, respectively. TRAIL decreases the release of OPG from cells that express it, while OPG inhibits TRAIL-induced apoptosis. Expression of RANK L on the cell surface, and thus its ability to stimulate osteoclastogenesis, is regulated by OPG by intracellular and extracellular mechanisms. Within osteoblasts, interaction of the basic domain of OPG with RANK L in the Golgi inhibits RANK L secretion.

       

      Product Properties

       

      Synonyms

      TNFRSF11B, Osteoclastogenesis Inhibitory Factor, Tumor Necrosis Factor Receptor Superfamily Member
      11B

      Accession
      O00300
      GeneID
      4982

      Source

      E.coli-derived Human OPG, Glu22-Lys194.
      Molecular Weight
      Approximately 19.7 kDa.
      AA Sequence
      ETFPPKYLHY DEETSHQLLC DKCPPGTYLK QHCTAKWKTV CAPCPDHYYT DSWHTSDECL YCSPVCKELQ YVKQECNRTH NRVCECKEGR YLEIEFCLKH RSCPPGFGVV QAGTPERNTV
      CKRCPDGFFS NETSSKAPCR KHTNCSVFGL LLTQKGNATH DNICSGNSES TQK
      Tag
      None
      Physical Appearance
      Sterile Filtered White lyophilized (freeze-dried) powder.
      Purity
      > 95 % by SDS-PAGE and HPLC analyses.
      Biological Activity
      The ED50 as determined by neutralizing the stimulation of U937 cells is less than 10 ng/mL, corresponding to a specific activity of > 1.0 × 10 5 IU/mg in the presence of 10 ng/mL soluble rHuRANKL (sRANKL). Fully biologically active when compared to standard.
      Endotoxin
      < 1.0 EU per 1μg of the protein by the LAL method.
      Formulation
      Lyophilized from a 0.2 μm filtered concentrated solution in 20 mM PB,150 mM NaCl, pH 6.0.
      Reconstitution
      We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20℃. Further dilutions should be made in appropriate buffered solutions.

       

      Storage

       

      The products are shipped with ice pack and can be stored at -20℃ to -80℃ for 1 year.
      Recommend to aliquot the protein into smaller quantities when first used and avoid repeated freeze-thaw cycles.

       

      Caution

       

      1. Avoid repeated freeze-thaw cycles.
      2. For your safety and health, please wear lab coats and disposable gloves for operation.
      3. For research use only!

      © 2024 Arcegen, Powered by Shopify

      • American Express
      • Apple Pay
      • Diners Club
      • Discover
      • Meta Pay
      • Google Pay
      • Mastercard
      • Shop Pay
      • Visa

      Login

      Forgot your password?

      Don't have an account yet?
      Create account